计算机化临床决策支持工具提高MASLD晚期纤维化风险患者的确认检测率
该研究在3个基层诊所实施计算机化临床决策支持工具(cCDS),针对FIB-4>1.3且伴糖尿病或≥2项代谢危险因素的MASLD患者,提示进行弹性成像和/或专科转诊。结果显示确认检测率从0%升至2.1%(P<0.001),专科转诊率从4%升至20%(P=0.12),但工具被忽略率高达75.4%。
要点
- cCDS工具触发条件为FIB-4>1.3且伴糖尿病或≥2项代谢危险因素。
- 确认检测率从0%升至2.1%(P<0.001),专科转诊率从4%升至20%(P=0.12)。
- 工具被忽略率75.4%,总体检测率仍低。
核心结论
- 实施cCDS工具可提高高危MASLD患者的确认检测和专科转诊率,但总体率仍低,可能与工具高忽略率有关。
研究设计与样本
- 在3个基层诊所实施cCDS工具为期3个月的干预研究,主要结局为确认检测/进一步评估的医嘱比例。
主要发现
- 干预诊所cCDS工具在1410次就诊中触发。
- 确认检测率从0%升至2.1%(P<0.001)。
- 专科转诊率从4%升至20%(P=0.12)。
- cCDS在75.4%的就诊中被忽略。
关键数值与推荐
- cCDS触发标准:FIB-4>1.3且伴糖尿病,或≥2项代谢危险因素。
- cCDS提示进行弹性成像和/或专科转诊。
临床怎么用
- 在基层可试用cCDS工具识别MASLD晚期纤维化高危患者并提示确认检测或转诊。
- 需优化触发标准和用户界面以提高工具使用率。
局限性
- 研究仅在三家诊所实施三个月,工具被忽略率高达75.4%,可能影响效果评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic-dysfunction associated steatotic liver disease (MASLD) is highly prevalent in primary care. The Fibrosis-4 (FIB-4) index noninvasively risk-stratifies patients needing confirmatory testing for advanced fibrosis. However, screening is underutilized, contributing to underdiagnosis and low rates of testing at-risk patients. Computerized clinical decision support (cCDS) tools can enhance recognition of MASLD and guide clinicians to appropriate care pathways. We aimed to determine if a cCDS tool identifying patients with MASLD at increased risk for advanced fibrosis improves rates of confirmatory testing and subspecialist referral. METHODS: The cCDS tool was implemented in 3 primary care clinics for a 3-month period. The cCDS tool triggered if an encounter met criteria for high or indeterminate FIB-4 score (> 1.3) plus diabetes, or ≥ 2 metabolic risk factors. The cCDS prompted testing with elastography and/or subspecialty referral. The primary outcome was proportion of encounters in which confirmatory testing/further evaluation was ordered. RESULTS: In intervention clinics, the cCDS tool triggered during 1410 encounters. Confirmatory testing increased from 0% to 2.1% (P < 0.001) and subspecialty referral increased from 4% to 20% (P = 0.12). The cCDS was ignored in 75.4% of encounters. CONCLUSIONS: Implementation of a cCDS tool increased rates of confirmatory testing and subspecialty referrals in at-risk patients, though overall rates remained low, likely related to high rates of ignoring the tool. This study demonstrates the feasibility of utilizing a cCDS tool in primary care to screen for patients with MASLD who are in highest need of further evaluation. Further optimization of triggering criteria and user interface may increase use of the tool.
引用
- Xiao T, Miller J, Rowland B, et al. A Computerized Clinical Decision Support Tool Increases Rates of Confirmatory Testing in MASLD Patients at Risk for Advanced Fibrosis. J Am Board Fam Med. 2026. PMID: 42660653. doi:10.3122/jabfm.2025.250261R0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。